Chronic myelogenous leukemia is a rare type of cancer that the increased and uncontrolled growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. Most of them people don’t know that they are infected with this kind of rare cancer and report shows that due to the smoking habits and exposure to high radiation for the time period.
Treatment of refractory chronic lymphocytic leukemia may include the following: Repeat treatment with monoclonal antibody therapy and combination chemotherapy. A clinical trial of chemotherapy with stem cell transplant.
Major research on disease:
CLL patients are encouraged to explore clinical trials. Clinical trials test new drugs and treatments, many of which are being supported by LLS research programs, before they are approved by the FDA as standard treatment. Present ongoing present trend of clinical researched are follows Kinase Inhibitor Therapy, Monoclonal Antibody, Immunomodulatory Drug and Improvements in Stem Cell Transplantation.
Incidence in males decreased slightly from 1.2 per 100.000 person years (PY) in 1989-2000 to 0.9 in 2001-2012. For females, incidence remained stable with 0.7 per 100.000 PY in both periods. Incidence was age dependent and highest in males in the last decades of life. Treatment before 2000 mainly consisted of chemotherapy, while after 2007 TKI use was 88%. Five-year relative survival was only 36%.